DC
PCRX icon

Diametric Capital’s Pacira BioSciences PCRX Stock Holding History

Diametric Capital’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-18,110
Closed -$950K – 160
2020
Q2 		$950K Buy
18,110
+2,680
+17% +$112K 0.73% 57
2020
Q1 		$517K Sell
15,430
-2,643
-15% -$110K 0.63% 56
2019
Q4 		$819K Buy
18,073
+3,734
+26% +$159K 0.6% 70
2019
Q3 		$546K Sell
14,339
-7,609
-35% -$304K 0.45% 67
2019
Q2 		$955K Buy
+21,948
New +$932K 0.61% 57

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SCM
Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Diametric Capital's PCRX Position: Q3 2020 in Review

Diametric Capital sold out of Pacira BioSciences (PCRX) in Q3 2020, closing a stake of 18,110 shares — an estimated $950K sold.

Diametric Capital first reported a position in PCRX in Q2 2019 and held it in 5 quarters. The position peaked at $955K in Q2 2019. 257 funds tracked by Wall St. Rank hold PCRX as of Q3 2020.

  • Diametric Capital reported no remaining Pacira BioSciences position as of Q3 2020 after selling out during the quarter.
  • Diametric Capital sold 18,110 Pacira BioSciences shares in Q3 2020, an estimated $950K.
  • Diametric Capital first reported a position in Pacira BioSciences in Q2 2019 and held it in 5 quarters.
  • Diametric Capital's Pacira BioSciences position peaked at $955K in Q2 2019.
  • 257 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2020.

Based on Diametric Capital's 13F filing for Q3 2020, filed 13 Nov 2020.